WO2012054501A1 - Human multipotent embryonic stem cell-like progenitor cells - Google Patents
Human multipotent embryonic stem cell-like progenitor cells Download PDFInfo
- Publication number
- WO2012054501A1 WO2012054501A1 PCT/US2011/056737 US2011056737W WO2012054501A1 WO 2012054501 A1 WO2012054501 A1 WO 2012054501A1 US 2011056737 W US2011056737 W US 2011056737W WO 2012054501 A1 WO2012054501 A1 WO 2012054501A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- mcpcs
- human
- differentiation
- enriched population
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 51
- 210000004027 cell Anatomy 0.000 claims abstract description 123
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 114
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 114
- 210000001671 embryonic stem cell Anatomy 0.000 claims abstract description 12
- 239000000427 antigen Substances 0.000 claims abstract description 11
- 102000036639 antigens Human genes 0.000 claims abstract description 11
- 108091007433 antigens Proteins 0.000 claims abstract description 11
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims abstract description 10
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims abstract description 10
- 239000003102 growth factor Substances 0.000 claims abstract description 9
- 150000003431 steroids Chemical class 0.000 claims abstract description 9
- 238000012216 screening Methods 0.000 claims abstract description 6
- 230000009885 systemic effect Effects 0.000 claims abstract description 6
- 230000004069 differentiation Effects 0.000 claims description 52
- 210000001519 tissue Anatomy 0.000 claims description 25
- 230000001625 cardiomyogenic effect Effects 0.000 claims description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 230000000392 somatic effect Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 102100032912 CD44 antigen Human genes 0.000 claims description 11
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 11
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 10
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 10
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 10
- 239000003246 corticosteroid Substances 0.000 claims description 10
- 230000001272 neurogenic effect Effects 0.000 claims description 10
- 102100037241 Endoglin Human genes 0.000 claims description 9
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 9
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 9
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 9
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 9
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 9
- 102000036693 Thrombopoietin Human genes 0.000 claims description 9
- 108010041111 Thrombopoietin Proteins 0.000 claims description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 9
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 8
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 8
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 8
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 8
- 210000001691 amnion Anatomy 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 230000009816 chondrogenic differentiation Effects 0.000 claims description 8
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 8
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 210000004696 endometrium Anatomy 0.000 claims description 7
- 238000000684 flow cytometry Methods 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 7
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 230000002440 hepatic effect Effects 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 210000001136 chorion Anatomy 0.000 claims description 4
- 230000009762 endothelial cell differentiation Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 230000009815 adipogenic differentiation Effects 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000009818 osteogenic differentiation Effects 0.000 claims description 3
- 210000000603 stem cell niche Anatomy 0.000 claims description 3
- 210000003954 umbilical cord Anatomy 0.000 claims description 3
- 102000013275 Somatomedins Human genes 0.000 claims 2
- 239000002609 medium Substances 0.000 description 31
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 27
- 102000008730 Nestin Human genes 0.000 description 13
- 108010088225 Nestin Proteins 0.000 description 13
- 210000005055 nestin Anatomy 0.000 description 13
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 12
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003125 immunofluorescent labeling Methods 0.000 description 9
- 239000003550 marker Substances 0.000 description 8
- 210000002826 placenta Anatomy 0.000 description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 6
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 6
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 6
- 102000014429 Insulin-like growth factor Human genes 0.000 description 6
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 6
- 102000004987 Troponin T Human genes 0.000 description 6
- 108090001108 Troponin T Proteins 0.000 description 6
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002536 stromal cell Anatomy 0.000 description 6
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 5
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 5
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 5
- 102100025304 Integrin beta-1 Human genes 0.000 description 5
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 210000004991 placental stem cell Anatomy 0.000 description 5
- 102100022464 5'-nucleotidase Human genes 0.000 description 4
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 4
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- -1 CD31 Proteins 0.000 description 4
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 4
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 4
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 4
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 4
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 4
- 229960002756 azacitidine Drugs 0.000 description 4
- 210000005064 dopaminergic neuron Anatomy 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102100028652 Gamma-enolase Human genes 0.000 description 3
- 101710191797 Gamma-enolase Proteins 0.000 description 3
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 3
- 102000004903 Troponin Human genes 0.000 description 3
- 108090001027 Troponin Proteins 0.000 description 3
- 230000002293 adipogenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 230000001744 histochemical effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000002188 osteogenic effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 101000979321 Homo sapiens Neurofilament medium polypeptide Proteins 0.000 description 2
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 2
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 2
- 101710098224 Myosin regulatory light chain 2, atrial isoform Proteins 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 102100023055 Neurofilament medium polypeptide Human genes 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 101710150336 Protein Rex Proteins 0.000 description 2
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000003021 clonogenic effect Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000000982 vasogenic effect Effects 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- JCVRUTWJRIKTOS-UHFFFAOYSA-N 7h-purin-6-amine;sulfuric acid Chemical compound OS(O)(=O)=O.NC1=NC=NC2=C1NC=N2 JCVRUTWJRIKTOS-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102100028538 Guanylate-binding protein 4 Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 239000007756 Ham's F12 Nutrient Mixture Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101001058851 Homo sapiens Guanylate-binding protein 4 Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100026057 Myosin regulatory light chain 2, atrial isoform Human genes 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- FJXOGVLKCZQRDN-PHCHRAKRSA-N alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- FZCHYNWYXKICIO-FZNHGJLXSA-N cortisol 17-valerate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O FZCHYNWYXKICIO-FZNHGJLXSA-N 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001705 ectoderm cell Anatomy 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- G01N15/01—
-
- G01N15/149—
Definitions
- the present invention relates to a population of precursor/progenitor cells, particularly enriched with multipotent embryonic stem cell-like mesenchymal common progenitor cells (MCPCs), and method for enriching the same.
- MCPCs multipotent embryonic stem cell-like mesenchymal common progenitor cells
- hESCs Human embryonic stem cells
- hESCs Human embryonic stem cells
- MSCs Mesenchymal stem cells
- MSCs are multipotent stem cells that can differentiate into a variety of cell types. MSCs have been isolated from placenta, adipose tissue, lung, bone marrow, dental pulp, and blood. Cell types that MSCs have been shown to differentiate into in vitro or in vivo osteoblasts, chondrocytes, myocytes, adipocytes, and beta-pancreatic islets cells. MSCs were found to be rare in bone marrow, representing ⁇ 1 in 10,000 nucleated cells. Although not immortal, they have the ability to expand manyfold in culture while retaining their growth and multilineage potential. Pittenger et al.
- mesenchymal (stem) cells were uniformly positive for SH2, SH3, CD29, CD44, CD71, CD90, CD 106, CD 120a, CD 124, and many other surface proteins, while the mesenchymal cells were negative for other markers of the hematopoietic lineage, including the lipopolysaccharide receptors CD14, CD34, and the leukocyte common antigen CD45.
- MSCs are identified by the expression of many molecules including CD44 and CD 105 and are negative for the hematopoietic markers CD34, CD45, and CD 14.
- amniotic mesenchymal stromal cells and human chorionic mesenchymal stromal cells could be isolated from placenta.
- the surface antigen expression of these cells is given in Table A below, showing that they cannot express CD45, CD34, CD14 and HLA-DR (Parolini et al, Stem Cells 26: 300-311, 2008).
- Table A Specific antigen expression at passages 2-4 for amniotic mesenchymal stromal cells and human chorionic mesenchymal stromal cells
- Caplice (US 7,790,453 B2) taught blood-derived, adult smooth muscle progenitor cells which were positive for CD34.
- the smooth muscle progenitor cells disclosed by Caplice are not characterized as mesenchymal stromal stem/progenitor cells and said progenitor cells have limited differentiation potential.
- Lucas et al. (US 7,259,01 1 B2) taught isolated human pluripotent adult stem cells (PPASCs) expressing CD13, CD34, CD56, and CD117.
- the PPASCs according to Lucas et al. did not express CD 10, CD 14, and stage specific embryonic antigen SSEA2.
- the PPASCs are not characterized as mesenchymal stromal stem/progenitor cells, either.
- Hariri (US 7,468,276 B2) taught isolated human placental stem cells that are OCT4 + and CD34 + .
- the human placental stem cells disclosed by Hariri were SSEA3 " and SSEA4 " .
- the human placental stem cells of Hariri were not characterized as mesenchymal stromal stem/progenitor cells.
- Edinger et al. discloses non-adherent, CD34 + CD45 " stem cells isolated from placenta.
- the placental stem cells according to Edinger et al. are non-adherent, and thus were not mesenchymal.
- tissue engineering an enriched population of multipotent stem cells that are juvenile and prolonged self-renewal are desired.
- the present invention provides a plurality of embryonic stem cell-like precursor cells, which is an enriched population of multipotent human mesenchymal common progenitor cells (MCPCs).
- the cells are isolated from a human somatic tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells followed by a cell sorting by a cell antigen selected from the group consisting of CD34, CD1 17, CD133, CD201, GloboH and combination thereof, and cultured in a medium supplemented with at least one or more steroids, and one or more growth factors.
- MCPCs multipotent human mesenchymal common progenitor cells
- the invention provides an enriched population of multipotent human mesenchymal common progenitor cells (MCPCs), which are identified as mesenchymal stromal stem/progenitor cells having at least the following characteristics: CD14 + , CD34 + , CD117 + , CD133 + (AC133 + ), CD201 + , Nesting SSEA3 + , SSEA4 + , and GloboH + .
- MCPCs multipotent human mesenchymal common progenitor cells
- the invention provides a method for producing the enriched population of multipotent human MCPCs according to the invention, comprising isolating from a human somatic tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells followed by a cell sorting by a cell antigen selected from the group consisting of CD34, CD1 17, CD133, CD201, GloboH and combination thereof, and culturing in a medium supplemented with at least one or more steroids selected from the group consisting of a corticosteroid and cholesterol and one or more growth factors selected from the group consisting of epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), insulin, platelet-derived growth factor (PDGF), IL-6, and thrombopoietin (TPO).
- EGF epidermal growth factor
- FGF fibroblast growth factor
- IGF insulin-like growth factor
- PDGF platelet-derived growth factor
- IL-6 thrombop
- the invention provides a composition comprising the enriched population of multipotent human MCPCs according to the invention encapsulated in alginate.
- the invention provides a feeder cell layer for stem cell culture comprising the enriched population of multipotent human MCPCs of the invention.
- the invention provides a stem cell niche comprising the enriched population of multipotent human MCPCs according to the invention seeded on a scaffold.
- Fig. 1 shows the cell morphology of human placenta amnionic mesenchymal cells.
- Fig 1A is a phase contrast image of AM-MSCs-CD34 + cells.
- Fig IB is a phase contrast image of AM-MSCs-CD34 " cells.
- Fig. 2 shows the profiling of cell surface marker of AM-MSCs-CD34 + and AM-MSCs-CD34 " cells; wherein Fig. 2A shows the expression of CD29, CD44, CD73, CD90, CD105, CD31, CD56, EGFR, and PDGFR; and Fig. 2B shows the expression of CD34, CD1 17, CD133, SSEA1, SSEA3, SSEA4, GloboH, and CD201.
- FIG. 3 A provides a schematic illustration of neural and oligodendrocyte differentiation of CD34 sorted MSCs.
- Fig. 3B provides a schematic illustration of dopaminergic neuron differentiation of CD34 sorted MSCs.
- FIG. 4 shows TuJl, TH, and MAP2 expression of CD34 + or CD34 " AM-MSC after dopaminergic neuron induction
- Fig. 4A provides TuJl (top), GFAP (middle), and DAPI (bottom) immunofluorescence staining images of CD34 + AM-MSC induced neurons
- Fig. 4B provides TuJl (top), GFAP (middle), and DAPI (bottom) immunofluorescence staining images of CD34 " AM-MSC induced neurons
- Fig. 4C provides TH (top), MAP2 (middle), and DAPI (bottom) immunofluorescence staining images of CD34 + AM-MSC induced neurons
- Fig. 4D provides TH (top), MAP2 (middle), and DAPI (bottom) immunofluorescence staining images of CD34 " AM-MSC induced neurons.
- Fig. 5 shows the cell morphology of human endometrium mesenchymal cells; wherein Fig 5A is a phase contrast image of EnMSCs-CD34 + cells; and Fig. 5B is a phase contrast image of EnMSCs-CD34 " cells.
- Fig. 6 shows the cardiomyogenic differentiation potentials of EnMSCs-CD34 + ; wherein Fig 6A provides Troponin T (top), myosin heavy chain (MHC) (middle), and DAPI (bottom) immunofluorescence staining images of CD34 + EnMSCs after cardiomyogenic induction; and Fig 6B provides Troponin T (top), myosin heavy chain (MHC) (middle), and DAPI (bottom) immunofluorescence staining images of CD34 " EnMSCs after cardiomyogenic induction.
- Fig 6A provides Troponin T (top), myosin heavy chain (MHC) (middle), and DAPI (bottom) immunofluorescence staining images of CD34 " EnMSCs after cardiomyogenic induction.
- MHC myosin heavy chain
- DAPI bottom
- Fig. 7 shows the numbers of expanded hematopoietic stem cells (HSCs) with specific surface marker(s) when co-culturing with murine MS-5 feeder, MSCs-CD34 + feeder, or MSCs-CD34 " feeder.
- HSCs hematopoietic stem cells
- the article “a” or “an” means one or more than one (that is, at least one) of the grammatical object of the article, unless otherwise made clear in the specific use of the article in only a singular sense.
- a plurality of precursor cells are isolated from human somatic tissues, and identified as mesenchymal stromal stem/progenitor cells expressing at least CD14, CD34, CDl 17, CD133 (AC133), CD201, Nestin, SSEA3, SSEA4, and GloboH (called as "MCPCs").
- the MCPCs may be obtained by a method comprising the steps of isolating from a human somatic tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells followed by a cell sorting by a cell antigen selected from the group consisting of CD34, CDl 17, CD133, CD201, GloboH, and combination thereof, and culturing in a medium supplemented with at least one or more steroids selected from the group consisting of a corticosteroid, cholesterol, and combination thereof, and one or more growth factors selected from the group consisting of epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), insulin, platelet-derived growth factor (PDGF), IL-6, thrombopoietin (TPO), and combination thereof.
- the MCPCs of the invention adhere to a tissue culture surface, which is different from the CD34 + , CD45 " placental stem cells as disclosed in Edinger et al. (US 2008
- the MCPCs of the invention can be isolated from human somatic tissues including but not limited to neonatal placenta (e.g. amnion, chorion, and umbilical cord), endometrium, gingival, bone marrow, and adipose.
- the MCPCs are isolated from placenta, endometrium, and gingival. More preferably, the MCPCs are isolated from placenta amniotic tissue.
- the MCPCs isolated from placenta amniotic tissue are called as AM-MSCs-CD34 + cells; the MCPCs isolated from endometrium are called as EnMSCs-CD34 + cells; and the MCPCs isolated from gingival are called as GMSCs-CD34 + cells.
- AM-MSCs-CD34 + cells, EnMSCs-CD34 + cells, and GMSCs-CD34 + cells have consistent profiling of cell surface markers expression.
- the MCPCs exhibited sphere-like clonogenicty in early passages and expressed multipotent embryonic stem cell (ESCs) like characteristics in vitro.
- the MCPCs of the invention are shorter than CD34 " MSCs. Specifically, the MCPCs of the invention have a higher growth rate as compared to CD34 " MSCs or unsorted MSCs, indicating that MCPCs of the invention are more proliferative and younger.
- the MCPCs homogenously express embryonic (e.g. Oct-4, Nanog, Rex-1, Sox-2), sternness (e.g. CD1 17, CD34, CD44) surface antigens, in addition to present various lineage markers, including MSC (e.g. CD29, CD90, CD73, CD105, CD106), hem-angiogenic (e.g. AC133, CD34), myo-nurogenic (e.g. CD54, Nestin, NSE). Further, the MCPCs of the invention are prolonged self-renewal.
- the MCPCs e.g., AM-MSCs-CD34 + cells
- the MCPCs could retain their specific cell marker expression as CD34, CD54, CD1 17, and AC133 positive, and their MSC marker expression even after 20 passages.
- the invention provides an enriched population of multipotent human mesenchymal common progenitor cells (MCPCs), which are identified as mesenchymal stromal stem/progenitor cells which have at least the following characteristics: CD14 + , CD34 + , CD1 17 + , CD133 + (AC133 + ), CD201 + , Nesting SSEA3 + , SSEA4 + , and GloboH + .
- MCPCs multipotent human mesenchymal common progenitor cells
- the enriched population of multipotent human MCPCs further have at least one of the following characteristics: CD44 + , CD54 + , CD56 + , CD105 + , CD146 + , and PDGFR + .
- the enriched population of multipotent human MCPCs are identified as mesenchymal stromal stem/progenitor cells, having the following characteristics: CD14 + , CD34 + , CD1 17 + , CD133 + (AC133 + ), CD201 + , Nesting SSEA3 + , SSEA4 + , GloboH + , CD44 + , CD54 + , CD56 + , CD105 + , CD146 + and PDGFR + .
- the enriched population of multipotent human MCPCs have the potentials to differentiate into cells or tissues of ectodermal lineage, mesodermal lineage, and endodermal lineage.
- AM-MSCs-CD34 cells were examined and found that they were multipotent in differentiation of various types of somatic cells, including endoderm, mesoderm, or ectoderm cells.
- the enriched population of multipotent human MCPCs have the potentials of adipogenic differentiation, osteogenic differentiation, chondrogenic differentiation, neurogenic differentiation, cardiomyogenic differentiation, endothelial differentiation, and hepatic differentiation.
- the invention provides a method for producing an enriched population of multipotent human MCPCs, comprising isolating from a human somatic tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells and a cell sorting by a cell antigen selected from the group consisting of CD34, Nestin, CD1 17, CD133 and combination thereof; and culturing in a medium supplemented with at least one or more steroids and one or more growth factors.
- the term "steroid” refers to a type of organic compound that contains a specific arrangement of four cycloalkane rings that are joined to each other.
- the steroid used in the medium according to the method may be one selected from the group consisting of a corticosteroid, cholesterol and combination thereof.
- corticosteroid refers to a class of steroid hormone.
- examples of corticosteroid include but are not limited to a group A corticosteroid (e.g. hydrocortisone, hydrocortisone acetate, and cortisone acetate), a group B corticosteroid (e.g. triamcinolone acetonide, triamcinolone alcohol, and mometasone), a group C corticosteroid (e.g. betamethasone, betamethasone sodium phosphate, and dexamethasone), and a group D corticosteroid (e.g. hydrocortisone- 17-valerate, aclometasone dipropionate, and hydrocortisone- 17-butyrate).
- group A corticosteroid e.g. hydrocortisone, hydrocortisone acetate, and cortisone acetate
- group B corticosteroid e.g. triamcinolone
- growth factor refers to a naturally occurring substance capable of stimulating cellular growth, proliferation and cellular differentiation, which can regulate a variety of cellular processes, and typically act as signaling molecules between cells.
- the growth factor used in the medium according to the method may be one or more selected from the group consisting of epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), insulin, platelet-derived growth factor (PDGF), IL-6, thrombopoietin (TPO), and combination thereof.
- the medium may be further supplemented with and one or more vitamins.
- vitamin refers to a nutrient in tiny amounts by an organism.
- examples of vitamins include but are limited to vitamin A, vitamin B-complex, vitamin E, biotin, p-aminobenzoic acid, menadione, and combination thereof.
- the medium may be also supplemented with one or more compounds selected from the group consisting of uracil, sodium acetate, ribose, Guanine HC1, deoxyribose, adenosine, adenine sulphate, ferric nitrate and combination thereof.
- the cell sorting is performed by using fluorescence-activated cell sorting (FACS) flow cytometry.
- FACS fluorescence-activated cell sorting
- the cell sorting is a CD34, CD117, CD133, CD201, or GloboH cell antigen FACS.
- the MCPCs may be encapsulated in alginate to form a composition.
- a feeder cell layer for stem cell culture is provided as well.
- the feeder cell layer comprises the enriched population of multipotent human MCPCs of the invention.
- the enriched population of multipotent human MCPCs may be seeded on the scaffold to form a stem cell niche.
- the invention provides a better source of ESC-like clonogenic stem cells that are derived from non-embryonic neonatal or adult tissue and multipotent in differentiation to various types of cells, than known sources, such as ESCs.
- the MCPCs of the invention were found to be of proliferative ability and differentiation potentials. They are of a great potential to be used for clinical regenerative therapies.
- the invention is further described in the following non-limiting examples.
- Example 1 Preparation and Characterization of AM-MSCs-CD34 + Cells [0046] Amnionic Mesenchymal Cell Isolation
- amnionic epithelial cells (Am-EpCs)
- washed amnion membrane was cut into 2-3 cm 2 fragments and incubated in 100 ml of 0. 1% Trypsin-EDTA (Sigma; St Louis, MO) with 1 * Hanks balanced salt solution (Gibco; CAT# 14185-052; Grand Island, NY) for an about 250 cm 2 membrane, with 4 times of each 15 min reactions in water bath, at 37°C.
- AM-MSCs Collection of clonogenic amnionic mesenchymal stromal cells
- AM-MSCs amnionic mesenchymal cells isolation
- the Am-EpCs depleted amnion membrane was subjected to wash with Hank's buffer one time and digested with collagenase 1A at 37°C for 45-60 minutes.
- An appropriate volume of Hank's buffer and a 40 ⁇ nylon cell strainer were used to collect the clongenic AM-MSCs.
- AM-MSCs were plated in CELL-BIND T75 flasks at a density of 5 ⁇ 10 4 cells per cm 2 and incubated in a 5% CO2, 37°C.
- the collected AM-MSCs were incubated in a medium containing Medium 199 (the Ml 99 conditioned medium) [(Lonza CAT# 12-1 18F; Switzerland), supplemented with fetal bovine serum (FBS), epidermal growth factor (EGF), and hydrocortisone.
- FBS fetal bovine serum
- EGF epidermal growth factor
- hydrocortisone Fresh medium were changed in every 3-4 days during the purification incubation, and cells expanded to 80% confluence in 7 days.
- the attached culturing cells were harvested with 0. 1% Trypsin-EDTA, and split into the new passage culture with a seeding density of l lO 5 cells per T75 flask.
- the collected CM-MSCs can be cultured in RPMI- 1640 (GIBCO; Grand Island, NY) supplemented with fetal bovine serum (FBS) (10%), sodium pyruvate (0.1 mM), basic fibroblast growth factor (bFGF), and EGF (10 ng/ml). Cells were split when they reached to 70-80% confluence, the culture medium was changed every 3-4 days.
- FBS fetal bovine serum
- bFGF basic fibroblast growth factor
- EGF EGF
- the expanded primary AM-MSCs cultured at passages 2-3 were used to label with CD34 antibody.
- Up to 3 ⁇ 10 6 cells were sorted by a FACS Aria flow cytometry (BD Bioscience, San Jose, CA) following the manufacture's instruction.
- CD34 positive (CD34 + ) and CD34 negative (CD34 ) cells were then analyzed, sorted, and collected.
- AM-MSCs-CD34 + and AM-MSCs-CD34 populations were re-analyzed for the positive fraction and expanded in the Ml 99 conditioned medium as described above or the RPMI conditioned medium.
- the cell morphology of AM-MSCs (passage 3) are given in Fig. 1, wherein the shape of AM-MSCs-CD34 + cells (Fig. 1A) is shorter than AM-MSCs-CD34 " cells (Fig. IB) and both showed stable in later passages.
- the initial doubling time of AM-MSCs-CD34 " cells is about 42 hours, which is longer than that of AM-MSCs-CD34 + at being 34 hours.
- the CD34 expression of AM-MSCs would be checked for each five passages in the following days. After CD34 + sorting 20 passages, CD34 + AM-MSC could still retain their specific cell marker expression as CD34, CD54, CD1 17, and CD133 (AC133) positive and their MSC marker expression.
- CD34 + AM-MSC could express more CD117, CD133, SSEAl, SSEA3, SSEA4, Globo H, and CD201 than CD34 " AM-MSC (Fig. 2B).
- AM-MSCs-CD34 + cells express "early genes" including Sox-2, Oct-4, Rex-1, and Nanog, ectodermal lineage genes, e.g. neurogenic differentiation markers including Nestin, NSE, NFM, NCAM, MAP2, mesodermal lineage genes, e.g. cardiomyogenic differentiation markers including MyoD, GATA-4, and MLC-2a, and endodermal lineage genes, e.g. hepatic differentiation makers including Albumin and HGF.
- ectodermal lineage genes e.g. neurogenic differentiation markers including Nestin, NSE, NFM, NCAM, MAP2, mesodermal lineage genes, e.g. cardiomyogenic differentiation markers including MyoD, GATA-4, and MLC-2a
- endodermal lineage genes e.g. hepatic differentiation makers including Albumin and HGF.
- Example 2 Induction of Differentiation
- the AM-MSCs-CD34 + cells at the number of 2 ⁇ 10 5 at passage 5 were used for the vasculogenic differentiation induction.
- Harvested cells were cultured in EGM-2 medium (Cambrex) for a 7 days induction.
- AM-MSCs-CD34 + cells at passages 4-6 were harvested for induction of cardiomyogenic differentiation.
- a cardiomyocytic differentiation agent 5-azacytidine (Sigma) was added into the medium to make a 5 ⁇ final concentration.
- CD34 + AM-MSCs trans differentiated easily into cardiomyocytes expressing MyoD, GATA-4, MLC-2a genes (data not shown).
- the AM-MSCs-CD34 cells obtained by the method as mentioned in Example 1 and expanded passages 5-6 were used for multi-lineage differentiation inductions.
- the adipogenic, osteogenic, chondrogenic, and neurogenic differentiation protocols were used by the methods given below.
- the AM-MSCs or AM-MSCs-CD34 pre-conditioning in Dulbecco's modified Eagle's medium (DMEM/LG, GIBCO) supplemented with 10% FBS (Hyclone) were used for the lineage differentiation cultures shown as following:
- Adipogenesis DMEM/LG medium supplemented with 10% FBS, 0.5 mM isobutyl-methylxanthine, 1 ⁇ dexamethasone, 10 ⁇ insulin, 200 ⁇ indomethacin.
- Osteogenesis DMEM/LG medium supplemented with 10% FBS, 0.1 ⁇ dexamethasone, 50 ⁇ ascorbate-2 -phosphate, 10 mM ⁇ -glycerolphosphate.
- CM Chondrogenesis
- Neurogenesis DMEM/LG medium supplemented with 5 ⁇ g/ml insulin, 200 ⁇ indomethacin, 0.5 mM isobutyl-methylxanthine. (Reagents used above for differentiation were all from Sigma; St.Louis, MO)
- the cell density was 3 x l0 4 cells/cm 2 .
- a higher cell density of l-2x l0 5 /10 ⁇ was used for chondrosphere formation.
- Medium was changed every three to four days for all differentiation assays, and cells were fixed for histochemical staining after 14 days of adipogenic, osteogenic, chondrogenic differentiation. After 14 days, intracellular oil droplets were formed under Oil Red O stain, and calcified extracellular matrix was present and positive for von Kossa staining (data not shown).
- AM-MSCs-CD34 + cells formed cartilage ball in 3 days.
- AM-MSCs-CD34 + cells cultured in neurogenic differentiation medium (Zuk's protocol, P4, Day 21) exhibited neural morphology and expressed neural markers including Nestin, NSE, NFM, NCAM, and MPA2, while AM-MSCs-CD34 " cells did not (data not shown).
- Stepl Neurosphere Formation: Cells were seeded at a density of 1000 per well with neurosphere medium (NS medium).
- NS Medium DMEM/HG/F12 (1 : 1) + l x B27 + 20 ng/ml EGF + 20 ng/ml FGF2 +2 ⁇ g/ml Heparin.
- Primary neurospheres (selecting mainly floating neurospheres) larger than 75 um were counted after 7 days in vitro.
- Step2 Neural Differentiation Assay: Dissociated neurospheres to single cells by trypsin-EDTA solution and culture the cells with: DMEM/F12 + 5% FBS for 24 hrs. These cells were treated with specific neural cell differentiation medium.
- Fig. 3A is a schematic illustration of neural and oligodendrocyte differentiation of CD34 sorted MSCs.
- Fig. 3B is a schematic illustration of dopaminergic neuron differentiation of CD34 sorted MSCs.
- CD34 + AM-MSC induced neurons were TuJl, TH, and MAP2 positive, while only a small population of CD34 " AM-MSC induced neurons expressed said markers (Fig. 4).
- CD34 + AM-MSCs expressed early genes and showed multipotent differentiation potential. Specific gene expression of CD34 + AM-MSCs is provided in Table 2 below.
- Example 3 EnMSCs-CD34 + cells, GMSCs-CD34 + cells, and CD34 + MSCs Enriched from Other Somatic Tissues
- AM-MSCs-CD34 + cells, EnMSCs-CD34 + cells, and GMSCs-CD34 + cells were identified as having consistent profiling of cell surface marker expression.
- the mesenchymal common progenitor cells (MCPCs) of the invention were CD14 + , CD34 + , Nesting CD117 + , CD133 + (AC133 + ), SSEA3 + , and SSEA4 + . Further, the MCPCs of the invention were also characterized as CD44 + , CD54 + , CD105 + ,
- CD146 + CD146 + , or PDGFR + .
- Table 5 Potentials of endothelial differentiation and chondrogenic differentiation.
- EnMSCs CD34+ CD31+, KDR+, CD34+: Bigger cartilage ball (CD34+/CD34-) more tube formation. (Diameter > 2x).
- CD34- CD31+, KDR+, less CD34-: Little cartilage ball tube formation. (Diameter ⁇ 100 ⁇ ).
- GMSCs CD34+ CD31+, KDR+, CD34+: Bigger cartilage ball
- CD34- CD31+, KDR+, less CD34-: Little cartilage ball tube formation. (Diameter ⁇ 100 ⁇ ).
- Table 7 Potentials of neurogenic differentiation and cardiomyogenic differentiation.
- CD34- Myosin Heavy Chain+
- CD34- Nestin+, Troponin T-.
- EnMSCs CD34+ Nestin+, TuJl+, CD34+: Myosin Heavy Chain+, (CD34+/CD34-) GFAP-, Troponin T+.
- CD34- Myosin Heavy Chain+
- CD34- Nestin+, TuJl+, Troponin T-.
- GMSC CD34+ Nestin+, TuJl+, CD34+: Myosin Heavy Chain+,
- CD34- Myosin Heavy Chain+
- CD34- Nestin+, TuJl+, Troponin T-.
- CD34+ MSCs can be enriched from many other somatic tissues according to the method of the invention. Normally, only 2-3% of MSCs are CD34 + . After isolated and enriched in culture, percentage of CD34 + MSCs ranging from 15% to 78% depending on which tissue they were isolated from and the donor (See Table 8 below). The culture-enriched CD34 + MSCs can be subject to FACS cell sorting for further enrichment to obtain a population of MSCs enriched with 99% or more CD34+ MSCs.
- Example 4 MCPCs as Feeder Cells
- MCPCs of the invention were used to prepare a stromal feeder for expansion of hematopoietic stem cells (HSCs).
- Stromal cells MS-5, or MSCs
- 2 ⁇ 4 ⁇ 10 4 CD34 + mononuclear cells (M Cs) were co-cultured with feeder in 1 ml HSC medium (X- VIVO 10 + 50 ng/ml SCF + 50 ng/ml Flt-3L + (20 ng/ml)10U/ml TPO + 10 ng/ml IL-6).
- suspension cells were counted and subjected to flow cytometry analysis (for CD34+CD38-, CD34+CD133+, CD34+CXCR4+, etc.).
Abstract
The invention provides a plurality of embryonic stem cell-like progenitor cells, which are isolated from a human tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells and a cell sorting by a cell antigen selected from the group consisting of CD34, CD117, CD133, CD201, GloboH and combination thereof, and cultured in a medium supplemented with at least one or more steroids and one or more growth factors. The cells of the invention express CD34 and exhibit sphere-like clonogenicity in early passages and express multipotent embryonic stem cells (ESCs) like characteristics.
Description
TITLE
HUMAN MULTIPOTENT EMBRYONIC STEM CELL-LIKE PROGENITOR
CELLS
BACKGROUND OF THE INVENTION
Field of the Invention
[001] The present invention relates to a population of precursor/progenitor cells, particularly enriched with multipotent embryonic stem cell-like mesenchymal common progenitor cells (MCPCs), and method for enriching the same.
Description of Related Art
[002] In regenerative medicine, to identify a source of stem cells of high safety and efficacy is the first step of the development of bio materials for repairing and renewing damaged and defective tissues. Human embryonic stem cells (hESCs) can remain undifferentiated, if cultured under appropriate conditions, and begin to spontaneously differentiate into various types of cells, which is a good indication that a culture of embryonic stem cells is a source for producing various types of cells. However, it is not an efficient way because to control the differentiation of embryonic stem cells is required (see: Stem Cells: Scientific Progress and Future Research Directions. Department of Health and Human Services. June 2001.).
[003] Mesenchymal stem cells, or MSCs, are multipotent stem cells that can differentiate into a variety of cell types. MSCs have been isolated from placenta, adipose tissue, lung, bone marrow, dental pulp, and blood. Cell types that MSCs have been shown to differentiate into in vitro or in vivo osteoblasts, chondrocytes, myocytes, adipocytes, and beta-pancreatic islets cells. MSCs were found to be rare in bone marrow, representing ~1 in 10,000 nucleated cells. Although not immortal, they have the ability to expand manyfold in culture while retaining their growth and multilineage potential. Pittenger et al. (Science 284, 143 (1999)) discloses that isolated mesenchymal (stem) cells were uniformly positive for SH2, SH3, CD29, CD44, CD71, CD90, CD 106, CD 120a, CD 124, and many other surface proteins, while the mesenchymal cells were negative for other markers of the hematopoietic lineage, including the lipopolysaccharide receptors CD14, CD34, and the leukocyte common antigen CD45. MSCs are identified by the expression of many molecules including CD44 and CD 105 and are negative for the hematopoietic markers CD34, CD45, and CD 14.
[004] It was reported that amniotic mesenchymal stromal cells and human chorionic mesenchymal stromal cells could be isolated from placenta. The surface antigen expression of these cells is given in Table A below, showing that they cannot express CD45, CD34, CD14 and HLA-DR (Parolini et al, Stem Cells 26: 300-311, 2008).
[005] Table A. Specific antigen expression at passages 2-4 for amniotic mesenchymal stromal cells and human chorionic mesenchymal stromal cells
[006] Caplice (US 7,790,453 B2) taught blood-derived, adult smooth muscle progenitor cells which were positive for CD34. However, the smooth muscle progenitor cells disclosed by Caplice are not characterized as mesenchymal stromal stem/progenitor cells and said progenitor cells have limited differentiation potential.
[007] Lucas et al. (US 7,259,01 1 B2) taught isolated human pluripotent adult stem cells (PPASCs) expressing CD13, CD34, CD56, and CD117. The PPASCs according to Lucas et al. did not express CD 10, CD 14, and stage specific embryonic antigen SSEA2. The PPASCs are not characterized as mesenchymal stromal stem/progenitor cells, either.
[008] Hariri (US 7,468,276 B2) taught isolated human placental stem cells that are OCT4+ and CD34+. The human placental stem cells disclosed by Hariri were SSEA3" and SSEA4". The human placental stem cells of Hariri were not characterized as mesenchymal stromal stem/progenitor cells.
[009] Edinger et al. (US 2008/0206343 Al) discloses non-adherent, CD34+CD45" stem cells isolated from placenta. The placental stem cells according to Edinger et al. are non-adherent, and thus were not mesenchymal.
[0010] For tissue engineering, an enriched population of multipotent stem cells that are juvenile and prolonged self-renewal are desired.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides a plurality of embryonic stem cell-like
precursor cells, which is an enriched population of multipotent human mesenchymal common progenitor cells (MCPCs). The cells are isolated from a human somatic tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells followed by a cell sorting by a cell antigen selected from the group consisting of CD34, CD1 17, CD133, CD201, GloboH and combination thereof, and cultured in a medium supplemented with at least one or more steroids, and one or more growth factors. It was unexpectedly found in the invention that a polulation of multipotent human mesenchymal common progenitor cells (called as "MCPCs") expressed CD34, , which is different from known human mesenchymal stromal (stem) cells as not expressing CD34. The MCPCs cells of the invention exhibited sphere-like clonogenicty in early passages and expressed multipotent embryonic stem cells (ESCs) like characteristics.
[0011] In one aspect, the invention provides an enriched population of multipotent human mesenchymal common progenitor cells (MCPCs), which are identified as mesenchymal stromal stem/progenitor cells having at least the following characteristics: CD14+, CD34+, CD117+, CD133+ (AC133+), CD201+, Nesting SSEA3+, SSEA4+, and GloboH+.
[0012] In another aspect, the invention provides a method for producing the enriched population of multipotent human MCPCs according to the invention, comprising isolating from a human somatic tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells followed by a cell sorting by a cell antigen selected from the group consisting of CD34, CD1 17, CD133, CD201, GloboH and combination thereof, and culturing in a medium supplemented with at least one or more steroids selected from the group consisting of a corticosteroid and cholesterol and one or more growth factors selected from the group consisting of epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), insulin, platelet-derived growth factor (PDGF), IL-6, and thrombopoietin (TPO).
[0013] In one further aspect, the invention provides a composition comprising the enriched population of multipotent human MCPCs according to the invention encapsulated in alginate.
[0014] In yet aspect, the invention provides a feeder cell layer for stem cell culture comprising the enriched population of multipotent human MCPCs of the invention.
[0015] In further yet aspect, the invention provides a stem cell niche comprising the
enriched population of multipotent human MCPCs according to the invention seeded on a scaffold.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawing.
[0017] Fig. 1 shows the cell morphology of human placenta amnionic mesenchymal cells. Fig 1A is a phase contrast image of AM-MSCs-CD34+ cells. Fig IB is a phase contrast image of AM-MSCs-CD34" cells.
[0018] Fig. 2 shows the profiling of cell surface marker of AM-MSCs-CD34+ and AM-MSCs-CD34" cells; wherein Fig. 2A shows the expression of CD29, CD44, CD73, CD90, CD105, CD31, CD56, EGFR, and PDGFR; and Fig. 2B shows the expression of CD34, CD1 17, CD133, SSEA1, SSEA3, SSEA4, GloboH, and CD201.
[0019] Fig. 3 A provides a schematic illustration of neural and oligodendrocyte differentiation of CD34 sorted MSCs.
[0020] Fig. 3B provides a schematic illustration of dopaminergic neuron differentiation of CD34 sorted MSCs.
[0021] Fig. 4 shows TuJl, TH, and MAP2 expression of CD34+ or CD34" AM-MSC after dopaminergic neuron induction, wherein Fig. 4A provides TuJl (top), GFAP (middle), and DAPI (bottom) immunofluorescence staining images of CD34+ AM-MSC induced neurons; Fig. 4B provides TuJl (top), GFAP (middle), and DAPI (bottom) immunofluorescence staining images of CD34" AM-MSC induced neurons; Fig. 4C provides TH (top), MAP2 (middle), and DAPI (bottom) immunofluorescence staining images of CD34+ AM-MSC induced neurons; And Fig. 4D provides TH (top), MAP2 (middle), and DAPI (bottom) immunofluorescence staining images of CD34" AM-MSC induced neurons.
[0022] Fig. 5 shows the cell morphology of human endometrium mesenchymal cells; wherein Fig 5A is a phase contrast image of EnMSCs-CD34+ cells; and Fig. 5B is a phase contrast image of EnMSCs-CD34" cells.
[0023] Fig. 6 shows the cardiomyogenic differentiation potentials of EnMSCs-CD34+; wherein Fig 6A provides Troponin T (top), myosin heavy chain (MHC) (middle), and DAPI (bottom) immunofluorescence staining images of CD34+
EnMSCs after cardiomyogenic induction; and Fig 6B provides Troponin T (top), myosin heavy chain (MHC) (middle), and DAPI (bottom) immunofluorescence staining images of CD34" EnMSCs after cardiomyogenic induction.
[0024] Fig. 7 shows the numbers of expanded hematopoietic stem cells (HSCs) with specific surface marker(s) when co-culturing with murine MS-5 feeder, MSCs-CD34+ feeder, or MSCs-CD34" feeder.
DESCRIPTION OF THE EMBODIMENTS
[0025] As used herein, the article "a" or "an" means one or more than one (that is, at least one) of the grammatical object of the article, unless otherwise made clear in the specific use of the article in only a singular sense.
[0026] According to the invention, it is unexpectedly found that a plurality of precursor cells are isolated from human somatic tissues, and identified as mesenchymal stromal stem/progenitor cells expressing at least CD14, CD34, CDl 17, CD133 (AC133), CD201, Nestin, SSEA3, SSEA4, and GloboH (called as "MCPCs"). The MCPCs may be obtained by a method comprising the steps of isolating from a human somatic tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells followed by a cell sorting by a cell antigen selected from the group consisting of CD34, CDl 17, CD133, CD201, GloboH, and combination thereof, and culturing in a medium supplemented with at least one or more steroids selected from the group consisting of a corticosteroid, cholesterol, and combination thereof, and one or more growth factors selected from the group consisting of epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), insulin, platelet-derived growth factor (PDGF), IL-6, thrombopoietin (TPO), and combination thereof. The MCPCs of the invention adhere to a tissue culture surface, which is different from the CD34+, CD45" placental stem cells as disclosed in Edinger et al. (US 2008/0206343 Al).
[0027] The MCPCs of the invention can be isolated from human somatic tissues including but not limited to neonatal placenta (e.g. amnion, chorion, and umbilical cord), endometrium, gingival, bone marrow, and adipose. Preferably, the MCPCs are isolated from placenta, endometrium, and gingival. More preferably, the MCPCs are isolated from placenta amniotic tissue. According to the invention, the MCPCs isolated from placenta amniotic tissue are called as AM-MSCs-CD34+ cells; the MCPCs isolated from endometrium are called as EnMSCs-CD34+ cells; and the MCPCs isolated
from gingival are called as GMSCs-CD34+ cells. Specifically, AM-MSCs-CD34+ cells, EnMSCs-CD34+ cells, and GMSCs-CD34+ cells have consistent profiling of cell surface markers expression. In the invention, the MCPCs exhibited sphere-like clonogenicty in early passages and expressed multipotent embryonic stem cell (ESCs) like characteristics in vitro. Morphologically, the MCPCs of the invention are shorter than CD34" MSCs. Specifically, the MCPCs of the invention have a higher growth rate as compared to CD34" MSCs or unsorted MSCs, indicating that MCPCs of the invention are more proliferative and younger.
[0028] According to the invention, the MCPCs homogenously express embryonic (e.g. Oct-4, Nanog, Rex-1, Sox-2), sternness (e.g. CD1 17, CD34, CD44) surface antigens, in addition to present various lineage markers, including MSC (e.g. CD29, CD90, CD73, CD105, CD106), hem-angiogenic (e.g. AC133, CD34), myo-nurogenic (e.g. CD54, Nestin, NSE). Further, the MCPCs of the invention are prolonged self-renewal. According to some embodiments of the invention, the MCPCs (e.g., AM-MSCs-CD34+ cells) could retain their specific cell marker expression as CD34, CD54, CD1 17, and AC133 positive, and their MSC marker expression even after 20 passages.
[0029] Accordingly, the invention provides an enriched population of multipotent human mesenchymal common progenitor cells (MCPCs), which are identified as mesenchymal stromal stem/progenitor cells which have at least the following characteristics: CD14+, CD34+, CD1 17+, CD133+ (AC133+), CD201+, Nesting SSEA3+, SSEA4+, and GloboH+.
[0030] According to the invention, the enriched population of multipotent human MCPCs further have at least one of the following characteristics: CD44+, CD54+, CD56+, CD105+, CD146+, and PDGFR+. In one embodiment of the invention, the enriched population of multipotent human MCPCs are identified as mesenchymal stromal stem/progenitor cells, having the following characteristics: CD14+, CD34+, CD1 17+, CD133+ (AC133+), CD201+, Nesting SSEA3+, SSEA4+, GloboH+, CD44+, CD54+, CD56+, CD105+, CD146+ and PDGFR+.
[0031] According to the invention, the enriched population of multipotent human MCPCs have the potentials to differentiate into cells or tissues of ectodermal lineage, mesodermal lineage, and endodermal lineage. In one embodiment of the invention,
AM-MSCs-CD34 cells were examined and found that they were multipotent in differentiation of various types of somatic cells, including endoderm, mesoderm, or ectoderm cells.
[0032] In one embodiment of the invention, the enriched population of multipotent human MCPCs have the potentials of adipogenic differentiation, osteogenic differentiation, chondrogenic differentiation, neurogenic differentiation, cardiomyogenic differentiation, endothelial differentiation, and hepatic differentiation.
[0033] In addition, the invention provides a method for producing an enriched population of multipotent human MCPCs, comprising isolating from a human somatic tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells and a cell sorting by a cell antigen selected from the group consisting of CD34, Nestin, CD1 17, CD133 and combination thereof; and culturing in a medium supplemented with at least one or more steroids and one or more growth factors.
[0034] As used herein, the term "steroid" refers to a type of organic compound that contains a specific arrangement of four cycloalkane rings that are joined to each other. In the invention, the steroid used in the medium according to the method may be one selected from the group consisting of a corticosteroid, cholesterol and combination thereof.
[0035] As used herein, the term "corticosteroid" refers to a class of steroid hormone. Examples of corticosteroid include but are not limited to a group A corticosteroid (e.g. hydrocortisone, hydrocortisone acetate, and cortisone acetate), a group B corticosteroid (e.g. triamcinolone acetonide, triamcinolone alcohol, and mometasone), a group C corticosteroid (e.g. betamethasone, betamethasone sodium phosphate, and dexamethasone), and a group D corticosteroid (e.g. hydrocortisone- 17-valerate, aclometasone dipropionate, and hydrocortisone- 17-butyrate).
[0036] The term "growth factor" as used herein refers to a naturally occurring substance capable of stimulating cellular growth, proliferation and cellular differentiation, which can regulate a variety of cellular processes, and typically act as signaling molecules between cells. In the invention, the growth factor used in the medium according to the method may be one or more selected from the group consisting of epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), insulin, platelet-derived growth factor (PDGF), IL-6,
thrombopoietin (TPO), and combination thereof.
[0037] According to some embodiments of the invention, the medium may be further supplemented with and one or more vitamins.
[0038] As used herein, the term "vitamin" refers to a nutrient in tiny amounts by an organism. In the invention, examples of vitamins include but are limited to vitamin A, vitamin B-complex, vitamin E, biotin, p-aminobenzoic acid, menadione, and combination thereof.
[0039] In the invention, the medium may be also supplemented with one or more compounds selected from the group consisting of uracil, sodium acetate, ribose, Guanine HC1, deoxyribose, adenosine, adenine sulphate, ferric nitrate and combination thereof.
[0040] In preferred embodiments of the invention, the cell sorting is performed by using fluorescence-activated cell sorting (FACS) flow cytometry. Preferably, the cell sorting is a CD34, CD117, CD133, CD201, or GloboH cell antigen FACS.
[0041] According to the invention, the MCPCs may be encapsulated in alginate to form a composition.
[0042] According to the invention, a feeder cell layer for stem cell culture is provided as well. The feeder cell layer comprises the enriched population of multipotent human MCPCs of the invention. Alternatively, the enriched population of multipotent human MCPCs may be seeded on the scaffold to form a stem cell niche.
[0043] Accordingly, the invention provides a better source of ESC-like clonogenic stem cells that are derived from non-embryonic neonatal or adult tissue and multipotent in differentiation to various types of cells, than known sources, such as ESCs. The MCPCs of the invention were found to be of proliferative ability and differentiation potentials. They are of a great potential to be used for clinical regenerative therapies. The invention is further described in the following non-limiting examples.
[0044] Human tissues used in the following examples were obtained using a protocol approved by Institutional Review Board of Cathay General Hospital & Taipei Medical University Institutional Review Board.
[0045] Example 1: Preparation and Characterization of AM-MSCs-CD34+ Cells [0046] Amnionic Mesenchymal Cell Isolation
[0047] (1) Isolation of amnion membrane:
[0048] Amnion membrane (about 300 cm2, n = 9) was stripped from chorion, washed in 3 χ 150 ml changes of 1 xHank's buffer to remove blood.
[0049] (2) Removal of the amnionic epithelial cells:
[0050] To deplete the amnionic epithelial cells (Am-EpCs), washed amnion membrane was cut into 2-3 cm2 fragments and incubated in 100 ml of 0. 1% Trypsin-EDTA (Sigma; St Louis, MO) with 1 * Hanks balanced salt solution (Gibco; CAT# 14185-052; Grand Island, NY) for an about 250 cm2 membrane, with 4 times of each 15 min reactions in water bath, at 37°C.
[0051 ] (3) Collection of clonogenic amnionic mesenchymal stromal cells (AM-MSCs):
[0052] For the amnionic mesenchymal cells (AM-MSCs) isolation, the Am-EpCs depleted amnion membrane was subjected to wash with Hank's buffer one time and digested with collagenase 1A at 37°C for 45-60 minutes. An appropriate volume of Hank's buffer and a 40 μιη nylon cell strainer were used to collect the clongenic AM-MSCs.
[0053] (4) Incubation of AM-MSCs:
[0054] After a 170g centrifugation, AM-MSCs were plated in CELL-BIND T75 flasks at a density of 5 χ 104 cells per cm2 and incubated in a 5% CO2, 37°C. The collected AM-MSCs were incubated in a medium containing Medium 199 (the Ml 99 conditioned medium) [(Lonza CAT# 12-1 18F; Switzerland), supplemented with fetal bovine serum (FBS), epidermal growth factor (EGF), and hydrocortisone. Fresh medium were changed in every 3-4 days during the purification incubation, and cells expanded to 80% confluence in 7 days. The attached culturing cells were harvested with 0. 1% Trypsin-EDTA, and split into the new passage culture with a seeding density of l lO5 cells per T75 flask.
[0055] Alternatively, the collected CM-MSCs can be cultured in RPMI- 1640 (GIBCO; Grand Island, NY) supplemented with fetal bovine serum (FBS) (10%), sodium pyruvate (0.1 mM), basic fibroblast growth factor (bFGF), and EGF (10 ng/ml). Cells were split when they reached to 70-80% confluence, the culture medium was changed every 3-4 days.
[0056] Flow Cytometry Analysis
[0057] For FACS analysis, freshly harvested AM-MSCs were trypsinized and
incubated with aliquot florescence (FITC or PE) conjugated monoclonal antibodies (mAbs), suggested by the manufacturer, for 30 minutes at 4°C in 100 μΐ phosphate buffer. Cell markers were tested including for the mesenchymal stem cell (MSC) lineage (CD29, CD90, CD73, CD105, CD106, Vimentin), sternness (CD34, CD44, CD1 17), hem-angiogenic (AC133, CD34), myo-neurogenic (CD54, Nestin), and myofibroblast markers (Vimentin, alpha smooth muscle actin). Cells were analyzed using a FACSCanto flow cytometry system (BD Bioscience, San Jose, CA). The flow-cytometric data were processed with FCS Express V3 software (De Novo; Canada).
[0058] Flow Cytometry Sorting
[0059] For isolation of the CD34+ AM-MSCs sub-population, the expanded primary AM-MSCs cultured at passages 2-3 were used to label with CD34 antibody. Up to 3 χ 106 cells were sorted by a FACS Aria flow cytometry (BD Bioscience, San Jose, CA) following the manufacture's instruction. CD34 positive (CD34+) and CD34 negative (CD34 ) cells were then analyzed, sorted, and collected.
[0060] In brief, 3-4 χ 106 harvested third passage AM-MSCs were trypsinized and labelled with PE-conjugated CD34 suggested by the manufacturer, for 15 minutes at room temperature in 100 μΐ phosphate buffer. Then filtered cells through a 40 μιη nylon cell strainer (Becton, Dickinson and Company CAT# 352235) and sorting AM-MSCs-CD34+ and AM-MSCs-CD34" populations with BD FACS Aria. After sorting, the AM-MSCs-CD34+ and AM-MSCs-CD34" populations were re-analyzed for the positive fraction and expanded in the Ml 99 conditioned medium as described above or the RPMI conditioned medium. The cell morphology of AM-MSCs (passage 3) are given in Fig. 1, wherein the shape of AM-MSCs-CD34+ cells (Fig. 1A) is shorter than AM-MSCs-CD34" cells (Fig. IB) and both showed stable in later passages. The initial doubling time of AM-MSCs-CD34" cells is about 42 hours, which is longer than that of AM-MSCs-CD34+ at being 34 hours. The CD34 expression of AM-MSCs would be checked for each five passages in the following days. After CD34+ sorting 20 passages, CD34+ AM-MSC could still retain their specific cell marker expression as CD34, CD54, CD1 17, and CD133 (AC133) positive and their MSC marker expression. It was found that the high expression each of CD and gene markers other than CD34 could be observed in the cells at each passage, but the expression of CD34 (50-60%) of
the cells at passage 1 was less than those of passages 3 or 9 (about 100%). Both CD34+ and CD34" sorted AM-MSC expressed CD29, CD44, CD73, CD90, CD105, EGFR positive, and CD31 negative. However, CD34+ AM-MSC expressed more CD56 and PDGFR than CD34" AM-MSC. See Figure 2A. Further, CD34+ AM-MSC could express more CD117, CD133, SSEAl, SSEA3, SSEA4, Globo H, and CD201 than CD34" AM-MSC (Fig. 2B). Specific gene expression was also examined by RT-PCR (data not shown). The results show that AM-MSCs-CD34+ cells express "early genes" including Sox-2, Oct-4, Rex-1, and Nanog, ectodermal lineage genes, e.g. neurogenic differentiation markers including Nestin, NSE, NFM, NCAM, MAP2, mesodermal lineage genes, e.g. cardiomyogenic differentiation markers including MyoD, GATA-4, and MLC-2a, and endodermal lineage genes, e.g. hepatic differentiation makers including Albumin and HGF.
[0061] Example 2: Induction of Differentiation
[0062] (1) Vasculogenic differentiation
[0063] The AM-MSCs-CD34+ cells at the number of 2 χ 105 at passage 5 were used for the vasculogenic differentiation induction. Harvested cells were cultured in EGM-2 medium (Cambrex) for a 7 days induction. Analysis of the capillary formation was performed using Matrigel (BD Biosciences). Specifically, after the induction culture, the AM-MSCs-CD34+ were trypsinized and plated onto Matrigel coated (Matrigel: M199 = 1 : 1) 24 well cluster, with a cell density of 105 cells per well. Capillary-like structures were observed by optical microscopy after 2, 4, 24, and 48 hours in the following 3 days.
[0064] (2) Cardiomyogenic differentiation
[0065] Sorted AM-MSCs-CD34+ cells at passages 4-6 were harvested for induction of cardiomyogenic differentiation. The AM-MSCs-CD34+ cells were incubated overnight in the growth medium [EGM-2:M199 (v:v = 1 :3) supplemented with 10% FBS, and MEM nonessential amino acids (l x) (GIBCO)]. On the next morning, cells were transferred into the cardiomyogenic differentiation medium, [IMDM (GIBCO): Ham's F12 nutrient mixture with GlutaMAX-1 (GIBCO) (v:v = 1 : 1) supplemented 2% horse serum (GIBCO), l x MEM nonessential amino acids, l x insulin-transferrin-selenium (GIBCO)] with a cell density of 104 per cm2. After 6-8 hours, a cardiomyocytic differentiation agent, 5-azacytidine (Sigma) was added into the
medium to make a 5 μΜ final concentration. 4ul/ml of 5-azacytidine (0.25 mM) stock solution was added into the differentiation medium daily, and changed back to the differentiation medium without 5-azacytidine on the day 4. On day six of the differentiation assay, ascorbic acid (10~4 M) (Sigma) and TGF-βΙ (1 ng/ml) (PeoproTech) were added to the medium. From this point forward, ascorbic acid and TGF-βΙ were supplemented every other days and twice weekly, respectively. The medium were changed every 2-3 days, depending on the medium pH changes. Cell debris should be removed by PBS washes, when medium changes. The Cardiomyogenic AM-MSCs-CD34+ cells were fixed for histochemical staining after 28-day differentiation culture. By a 5-azacytidine myogenic induction, CD34+ AM-MSCs (P5) trans differentiated easily into cardiomyocytes expressing MyoD, GATA-4, MLC-2a genes (data not shown). After cardiomyogenic differentiation 28 days and examined by histochemical staining, both CD34+ and CD34" AM-MSCs expressed myosin heavy chain (MHC), but only induced CD34+ AM-MSCs formed typical cardiomyocyte morphology and expressed terminal differentiated marker Troponin T (data not shown).
[0066] (3) Hepatic differentiation
[0067] The expressions of hepatic differentiation cell markers were given in Table 1 below.
Table 1. Expressions of hepatic differentiation cell markers of AM-MSCs-CD34+ cells (passage 6).
(4) Adipogenic, osteogenic, and chondrogenic differentiation
[0069] The AM-MSCs-CD34 cells obtained by the method as mentioned in Example 1 and expanded passages 5-6 were used for multi-lineage differentiation inductions. The adipogenic, osteogenic, chondrogenic, and neurogenic differentiation protocols were used by the methods given below.
[0070] The AM-MSCs or AM-MSCs-CD34 pre-conditioning in Dulbecco's modified Eagle's medium (DMEM/LG, GIBCO) supplemented with 10% FBS (Hyclone) were used for the lineage differentiation cultures shown as following:
1) Adipogenesis (AM): DMEM/LG medium supplemented with 10% FBS, 0.5 mM isobutyl-methylxanthine, 1 μΜ dexamethasone, 10 μΜ insulin, 200 μΜ indomethacin.
2) Osteogenesis (OM): DMEM/LG medium supplemented with 10% FBS, 0.1 μΜ dexamethasone, 50 μΜ ascorbate-2 -phosphate, 10 mM β-glycerolphosphate.
3) Chondrogenesis (CM): DMEM/LG medium supplemented with 1% FBS, 6.25 μ§/πύ insulin, 10 ng/ml TGF-βΙ (R&D), 50 nM ascorbate-2-phosphate.
4) Neurogenesis (NM): DMEM/LG medium supplemented with 5 μg/ml insulin, 200 μΜ indomethacin, 0.5 mM isobutyl-methylxanthine. (Reagents used above for differentiation were all from Sigma; St.Louis, MO)
[0071] For adipogenic, osteogenic, and neurogenic differentiation, the cell density was 3 x l04 cells/cm2. For chondrogenic differentiation, a higher cell density of l-2x l05/10 μΐ was used for chondrosphere formation. Medium was changed every three to four days for all differentiation assays, and cells were fixed for histochemical staining after 14 days of adipogenic, osteogenic, chondrogenic differentiation. After 14 days, intracellular oil droplets were formed under Oil Red O stain, and calcified extracellular matrix was present and positive for von Kossa staining (data not shown). In chondrogenic differentiation, AM-MSCs-CD34+ cells formed cartilage ball in 3 days. AM-MSCs-CD34+ cells cultured in neurogenic differentiation medium (Zuk's protocol, P4, Day 21) exhibited neural morphology and expressed neural markers including Nestin, NSE, NFM, NCAM, and MPA2, while AM-MSCs-CD34" cells did not (data not shown).
[0072] (5) Neurogenic differentiation
[0073] Stepl : Neurosphere Formation: Cells were seeded at a density of 1000 per well with neurosphere medium (NS medium). NS Medium: DMEM/HG/F12 (1 : 1) + l x B27 + 20 ng/ml EGF + 20 ng/ml FGF2 +2 μg/ml Heparin. Primary neurospheres (selecting mainly floating neurospheres) larger than 75 um were counted after 7 days in vitro. Step2: Neural Differentiation Assay: Dissociated neurospheres to single cells by trypsin-EDTA solution and culture the cells with: DMEM/F12 + 5% FBS for 24 hrs. These cells were treated with specific neural cell differentiation medium. The medium
used for neuronal differentiation was DMEM/F12 supplemented with 2% FBS, 10 ng/ml PDGF, 50 ng/ml BNDF, and 50 ng/ml GDNF. Fig. 3A is a schematic illustration of neural and oligodendrocyte differentiation of CD34 sorted MSCs. Fig. 3B is a schematic illustration of dopaminergic neuron differentiation of CD34 sorted MSCs.
[0074] After 7 to 9 days, the differentiation capacity was verified by using immunofluorescence staining (GFAP conjugated with FITC, Hochest 33258, and TuJl conjugated with rhodamine). After primary neurosphere formation, CD34+ and CD34" AM-MSC both expressed TuJl (neuron specific marker). However, the GFAP (glia specific marker) expression was dim for CD34+ AM-MSC induced neurons. On the other hand, some CD34" AM-MSC induced neuron expressed GFAP, which suggests that some induced CD34" AM-MSC cells differentiate into neurons while some of them differentiate into glia cells. In B27 induction, CD34+ AM-MSC expressed Gale, and TuJl, but not GFAP. For dopaminergic neuron differentiation, as detected by immunofluorescence staining, CD34+ AM-MSC induced neurons were TuJl, TH, and MAP2 positive, while only a small population of CD34" AM-MSC induced neurons expressed said markers (Fig. 4).
[0075] (6) Conclusion
[0076] CD34+ AM-MSCs expressed early genes and showed multipotent differentiation potential. Specific gene expression of CD34+ AM-MSCs is provided in Table 2 below.
[0077] Table 2. Summary of CD34+ AM-MSCs gene expression.
[0079] Primary endometrial and gingival tissues were collected from donors from Taipei medical hospital and Dr. Wells Dental clinic follows the IRB guide line. EnMSCs and GMSCs were obtained from endometrial and gingival tissues, respectively, by similar process set forth in Example 1. EnMSCs and GMSCs were then subject to CD34 sorting.
[0080] Phase contrast images of CD34 sorted human endometrium derived mesenchymal stem cells (P5) are given in Fig. 5. The morphology of EnMSCs-CD34+ cells was very similar to AM-MSCs-CD34+. Further, as provided in Table 3 below,
AM-MSCs-CD34+ cells, EnMSCs-CD34+ cells, and GMSCs-CD34+ cells were identified as having consistent profiling of cell surface marker expression.
Specifically, the mesenchymal common progenitor cells (MCPCs) of the invention were CD14+, CD34+, Nesting CD117+, CD133+ (AC133+), SSEA3+, and SSEA4+. Further, the MCPCs of the invention were also characterized as CD44+, CD54+, CD105+,
CD146+, or PDGFR+.
[0081] Table 3. Cell surface markers expression of MCPCs and CD34" MSCs. Percentage of FACS markers expression: -: 0-20%, +: 20-40%, ++: 40-80%, +++: 80-100%.
CD54 +++ + +++ + +++ +
PDGFR ++ + ++ + ++ +
Nestin +++ + +++ + +++ +
CD14 +++ - +++ - +++ -
CD117 +++ - +++ - +++ -
AC133 +++ - +++ - +++ -
CD 146 +++ - +++ - +++ -
[0082] The comparison on cell morphologies and cell doubling times of MCPCs and CD34" MSCs are given in Table 4 below.
[0083] Table 4. Comparison of cell morphology and cell doubling time.
[0085] Table 5. Potentials of endothelial differentiation and chondrogenic differentiation.
EnMSCs CD34+: CD31+, KDR+, CD34+: Bigger cartilage ball (CD34+/CD34-) more tube formation. (Diameter > 2x).
CD34-: CD31+, KDR+, less CD34-: Little cartilage ball tube formation. (Diameter < 100 μιη).
GMSCs CD34+: CD31+, KDR+, CD34+: Bigger cartilage ball
(CD34+/CD34-) more tube formation. (Diameter > 2x).
CD34-: CD31+, KDR+, less CD34-: Little cartilage ball tube formation. (Diameter < 100 μιη).
[0086] Comparison of embryonic gene expression of MCPCs and CD34" MSCs are given in Table 6 below. MCPCs of the invention showed stronger embryonic gene expression than CD34" MSCs.
[0087] Table 6. Comparison of embryonic gene expression
[0088] Potentials of neurogenic differentiation and cardiomyogenic differentiation of MCPCs and CD34" MSCs are given in Table 7 below. The cardiomyogenic marker immunofluorescence staining images of EnMSCs are as shown in Fig. 6.
[0089] Table 7. Potentials of neurogenic differentiation and cardiomyogenic differentiation.
Neurogenic Differentiation Cardiomyogenic Differentiation
AM-MSCs CD34+: Nestin+, TuJl+, CD34+: Myosin Heavy Chain+, (CD34+/CD34-) GFAP-, typical neuron Troponin T+.
forming. CD34-: Myosin Heavy Chain+,
CD34-: Nestin+, Troponin T-.
TuJl (less+), GFAP-
EnMSCs CD34+: Nestin+, TuJl+, CD34+: Myosin Heavy Chain+, (CD34+/CD34-) GFAP-, Troponin T+.
neurosphere-like structure. CD34-: Myosin Heavy Chain+,
CD34-: Nestin+, TuJl+, Troponin T-.
GFAP-
GMSC CD34+: Nestin+, TuJl+, CD34+: Myosin Heavy Chain+,
(CD34+/CD34-) GFAP-, Troponin T+.
neurosphere-like structure. CD34-: Myosin Heavy Chain+,
CD34-: Nestin+, TuJl+, Troponin T-.
GFAP-
[0090] CD34+ MSCs can be enriched from many other somatic tissues according to the method of the invention. Normally, only 2-3% of MSCs are CD34+. After isolated and enriched in culture, percentage of CD34+ MSCs ranging from 15% to 78% depending on which tissue they were isolated from and the donor (See Table 8 below). The culture-enriched CD34+ MSCs can be subject to FACS cell sorting for further enrichment to obtain a population of MSCs enriched with 99% or more CD34+ MSCs.
[0091 ] Table 8. Enrichment of Stem/progenitor marker and gene expressions in Human Tissue MSCs
Adipose 15 - 30 (-23)
[0092] Example 4: MCPCs as Feeder Cells
[0093] MCPCs of the invention were used to prepare a stromal feeder for expansion of hematopoietic stem cells (HSCs). Stromal cells (MS-5, or MSCs) were seeded in plate and wait for confluence to become feeder. 2~4χ 104 CD34+ mononuclear cells (M Cs) were co-cultured with feeder in 1 ml HSC medium (X- VIVO 10 + 50 ng/ml SCF + 50 ng/ml Flt-3L + (20 ng/ml)10U/ml TPO + 10 ng/ml IL-6). After 7 days or 14 days, suspension cells were counted and subjected to flow cytometry analysis (for CD34+CD38-, CD34+CD133+, CD34+CXCR4+, etc.).
[0094] The results are shown in Fig. 7. When co-culturing with the MCPCs (AM-MSCs-CD34+ cells) feeder, more engrafting CD34+CD38- primitive HSCs were obtained, as compared to murine MS-5 feeder or MSCs-CD34" feeder.
[0095] Although the present invention is illustrated by the above embodiments, these embodiments are not used to limit the present invention. It will be apparent to those skilled in the art that various modifications and variations can be made to the structure of the present invention without departing from the scope or spirit of the invention. In view of the foregoing, it is intended that the present invention cover modifications and variations of this invention provided they fall within the scope of the following claims and their equivalents.
Claims
1. An enriched population of multipotent human mesenchymal common progenitor cells (MCPCs), which are identified as mesenchymal stromal stem/progenitor cells, having at least the following characteristics: CD14+, CD34+, CD117+, CD133+ (AC133+), CD201+, Nesting SSEA3+, SSEA4+ and GloboH+.
2. The enriched population of multipotent human MCPCs according to claim 1, wherein the MCPCs further have at least one of the following characteristics: CD44+, CD54+, CD56+, CD105+, CD146+, and PDGFR+.
3. The enriched population of multipotent human MCPCs according to claim 1, which exhibit sphere-like clonogenicty in early passages and express multipotent embryonic stem cells (ESCs) like characteristics.
4. The enriched population of multipotent human MCPCs according to claim 1, which are mesenchymal stromal stem/progenitor cells having the following characteristics: CD14+, CD34+, CD117+, CD133+ (AC133+), CD201+, Nesting SSEA3+, SSEA4+, GloboH+, CD44+, CD54+, CD56+, CD105+, CD146+ and
PDGFR+.
5. The enriched population of multipotent human MCPCs according to claim 1, which is isolated from a human somatic tissue.
6. The enriched population of multipotent human MCPCs according to claim 5, wherein the human somatic tissue is selected from the group consist of amnion, chorion, umbilical cord, endometrium, gingival, bone marrow, and adipose.
7. The enriched population of multipotent human MCPCs according to claim 6, where the human somatic tissue is amnion.
8. The enriched population of multipotent human MCPCs according to claim 1, which has the potentials to differentiate into ectodermal cells, mesodermal cells, and endodermal cells.
9. The enriched population of multipotent human MCPCs according to claim 1, which has the potentials of adipogenic differentiation, osteogenic differentiation, chondrogenic differentiation, neurogenic differentiation, cardiomyogenic differentiation, endothelial differentiation, and hepatic differentiation.
10. A method for producing the enriched population of multipotent human MCPCs according to claim 1, comprising: isolating from a human somatic tissue by a systemic screening of human mesenchymal stromal stem/progenitor cells followed by a cell sorting by a cell antigen selected from the group consisting of CD34, CD117, CD133, CD201, GloboH and combination thereof; and
culturing in a medium supplemented with at least one or more steroids and one or more growth factors.
11. The method according to claim 10, wherein the human somatic tissue is selected from the group consist of amnion, chorion, umbilical cord, endometrium, gingival, bone marrow, and adipose
12. The method according to claim 10, wherein the cell sorting is a fluorescence-activated cell sorting (FACS) flow cytometry.
13. The method according to claim 10, wherein the steroid is one selected from the group consisting of a corticosteroid, cholesterol and combination thereof.
14. The method according to claim 10, wherein the growth factor is one selected from the group consisting of epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), insulin, platelet-derived growth factor (PDGF), IL-6, thrombopoietin (TPO), and combination thereof.
15. A composition comprising the enriched population of multipotent human MCPCs according to claim 1, which are encapsulated in alginate.
16. A feeder cell layer for stem cell culture comprising the enriched population of multipotent human MCPCs according to claim 1.
17. A stem cell niche comprising the enriched population of multipotent human
MCPCs according to claim 1 seeded on a scaffold.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11835003.2A EP2630234B1 (en) | 2010-10-18 | 2011-10-18 | Human multipotent embryonic stem cell-like progenitor cells |
| AU2011317203A AU2011317203B2 (en) | 2010-10-18 | 2011-10-18 | Human multipotent embryonic stem cell-like progenitor cells |
| KR1020137012722A KR20140001900A (en) | 2010-10-18 | 2011-10-18 | Human multipotent embryonic stem cell-like progenitor cells |
| CN201180057856.7A CN104204190B (en) | 2010-10-18 | 2011-10-18 | Human multipotent embryonic stem cell-like progenitor cells |
| CA2815097A CA2815097A1 (en) | 2010-10-18 | 2011-10-18 | Human multipotent embryonic stem cell-like progenitor cells |
| SG2013028279A SG189414A1 (en) | 2010-10-18 | 2011-10-18 | Human multipotent embryonic stem cell-like progenitor cells |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39407310P | 2010-10-18 | 2010-10-18 | |
| US61/394,073 | 2010-10-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012054501A1 true WO2012054501A1 (en) | 2012-04-26 |
| WO2012054501A9 WO2012054501A9 (en) | 2013-05-30 |
Family
ID=45934474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2011/056737 WO2012054501A1 (en) | 2010-10-18 | 2011-10-18 | Human multipotent embryonic stem cell-like progenitor cells |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9234177B2 (en) |
| EP (1) | EP2630234B1 (en) |
| KR (1) | KR20140001900A (en) |
| CN (1) | CN104204190B (en) |
| AU (1) | AU2011317203B2 (en) |
| CA (1) | CA2815097A1 (en) |
| SG (1) | SG189414A1 (en) |
| TW (1) | TWI523947B (en) |
| WO (1) | WO2012054501A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014027474A1 (en) * | 2012-08-17 | 2014-02-20 | 株式会社Ｃｌｉｏ | Pluripotent stem cell that induces repair and regeneration after myocardial infarction |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011032166A2 (en) * | 2009-09-14 | 2011-03-17 | The Johns Hopkins University | Reprogramming blood cells to pluripotent and multipotent stem cells |
| EP3613847A1 (en) * | 2013-03-13 | 2020-02-26 | The University of Queensland | A method of isolating cells for therapy and prophylaxis |
| EP3004328A4 (en) * | 2013-05-30 | 2016-12-07 | Cells For Cells | Chorion-derived mscs cells and conditioned media as inducer for angiogenesis application for the treatment of cardiac degeneration. |
| BR102013033827B1 (en) | 2013-12-27 | 2021-09-08 | Regenera - Medicina Veterinária Avançada Ltda. | MULTIPOTENT AND IMMUNOCOMPATIBLE CONCENTRATE OF STEM CELLS AND BIOPHARMACEUTICALS AND DOSAGE FORM THAT INCLUDE IT |
| KR20230067696A (en) * | 2016-06-23 | 2023-05-16 | 티톤 바이오테크, 인크. | Cells expressing parathyroid hormone 1 receptor and uses thereof |
| US11103537B2 (en) | 2016-06-23 | 2021-08-31 | Tithon Biotech Inc. | Cells expressing parathyroid hormone 1 receptor and uses thereof |
| CN108728408B (en) * | 2018-05-28 | 2021-08-24 | 天津博雅秀岩生物技术有限公司 | Canine fetal membrane mesenchymal stem cell, preparation method and culture medium used by same |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1605040A1 (en) | 2003-03-18 | 2005-12-14 | Keio University | Monocyte-origin multipotent cell momc |
| US20070122903A1 (en) * | 2005-05-27 | 2007-05-31 | Alireza Rezania | Amniotic fluid derived cells |
| US7259011B2 (en) | 2004-05-20 | 2007-08-21 | Paul Lucas | Pluripotent adult stem cells |
| WO2008036374A2 (en) | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
| US20080206343A1 (en) | 2007-02-12 | 2008-08-28 | Edinger James W | Hepatocytes and Chondrocytes from Adherent Placental StemCells; And CD34+ ,CD45- Placental Stem Cell-Enriched Cell Populations |
| US20080213228A1 (en) * | 2006-10-23 | 2008-09-04 | Anthrogenesis Corporation | Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations |
| US20080241171A1 (en) * | 2004-02-11 | 2008-10-02 | Aldagen , Inc. | Stem Cell Populations and Methods of Use |
| US7468276B2 (en) | 2000-12-06 | 2008-12-23 | Anthrogenesis Corporation | Placental stem cells |
| WO2009045201A1 (en) * | 2006-08-02 | 2009-04-09 | Biogen Idec Ma Inc. | Cancer stem cells |
| US20100124569A1 (en) * | 2008-11-19 | 2010-05-20 | Abbot Stewart | Amnion derived adherent cells |
| US7790453B2 (en) | 2003-06-03 | 2010-09-07 | Mayo Foundation For Medical Education And Research | Smooth muscle progenitor cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1649007A4 (en) * | 2003-07-17 | 2008-05-14 | Gamida Cell Ltd | Methods for ex-vivo expanding stem/progenitor cells |
| WO2005113749A2 (en) * | 2004-05-14 | 2005-12-01 | Becton, Dickinson And Company | Stem cell populations and methods of use |
| JP5539649B2 (en) * | 2005-12-13 | 2014-07-02 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Scaffold for cell transplantation |
| JP2009525044A (en) * | 2006-01-30 | 2009-07-09 | ユニバーシティ オブ バージニア パテント ファウンデーション | Methods for preparing and characterizing mesenchymal stem cell aggregates and their use |
| PT103843B (en) * | 2007-10-04 | 2008-08-12 | Medinfar Produtos Farmaceutico | PRECURSOR CELL ISOLATION METHOD FROM THE HUMAN UMBILICAL CORD |
-
2011
- 2011-10-18 KR KR1020137012722A patent/KR20140001900A/en not_active Application Discontinuation
- 2011-10-18 SG SG2013028279A patent/SG189414A1/en unknown
- 2011-10-18 US US13/276,106 patent/US9234177B2/en not_active Expired - Fee Related
- 2011-10-18 CN CN201180057856.7A patent/CN104204190B/en not_active Expired - Fee Related
- 2011-10-18 CA CA2815097A patent/CA2815097A1/en not_active Abandoned
- 2011-10-18 TW TW100137771A patent/TWI523947B/en active
- 2011-10-18 EP EP11835003.2A patent/EP2630234B1/en not_active Not-in-force
- 2011-10-18 AU AU2011317203A patent/AU2011317203B2/en not_active Ceased
- 2011-10-18 WO PCT/US2011/056737 patent/WO2012054501A1/en active Application Filing
-
2015
- 2015-12-09 US US14/963,738 patent/US20160145577A1/en not_active Abandoned
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7468276B2 (en) | 2000-12-06 | 2008-12-23 | Anthrogenesis Corporation | Placental stem cells |
| EP1605040A1 (en) | 2003-03-18 | 2005-12-14 | Keio University | Monocyte-origin multipotent cell momc |
| US7790453B2 (en) | 2003-06-03 | 2010-09-07 | Mayo Foundation For Medical Education And Research | Smooth muscle progenitor cells |
| US20080241171A1 (en) * | 2004-02-11 | 2008-10-02 | Aldagen , Inc. | Stem Cell Populations and Methods of Use |
| US7259011B2 (en) | 2004-05-20 | 2007-08-21 | Paul Lucas | Pluripotent adult stem cells |
| US20070122903A1 (en) * | 2005-05-27 | 2007-05-31 | Alireza Rezania | Amniotic fluid derived cells |
| WO2009045201A1 (en) * | 2006-08-02 | 2009-04-09 | Biogen Idec Ma Inc. | Cancer stem cells |
| WO2008036374A2 (en) | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
| US20080213228A1 (en) * | 2006-10-23 | 2008-09-04 | Anthrogenesis Corporation | Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations |
| US20080206343A1 (en) | 2007-02-12 | 2008-08-28 | Edinger James W | Hepatocytes and Chondrocytes from Adherent Placental StemCells; And CD34+ ,CD45- Placental Stem Cell-Enriched Cell Populations |
| US20100124569A1 (en) * | 2008-11-19 | 2010-05-20 | Abbot Stewart | Amnion derived adherent cells |
Non-Patent Citations (5)
| Title |
|---|
| "Stem Cells: Scientific Progress and Future Research Directions", June 2001 |
| JEONG KYU LEE ET AL.: "Progenitor Cells in Healing after Pterygium Excision", YONSEI MEDICAL JOURNAL, vol. 48, no. 1, 2007, pages 48 - 54, XP055101705, DOI: doi:10.3349/ymj.2007.48.1.48 |
| PAROLINI ET AL., STEM CELLS, vol. 26, 2008, pages 300 - 311 |
| PITTENGER ET AL., SCIENCE, vol. 284, 1999, pages 143 |
| See also references of EP2630234A4 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014027474A1 (en) * | 2012-08-17 | 2014-02-20 | 株式会社Ｃｌｉｏ | Pluripotent stem cell that induces repair and regeneration after myocardial infarction |
| JPWO2014027684A1 (en) * | 2012-08-17 | 2016-07-28 | 株式会社Ｃｌｉｏ | Pluripotent stem cells that induce repair and regeneration of myocardial infarction |
| EP3659612A1 (en) * | 2012-08-17 | 2020-06-03 | Clio, Inc. | Pluripotent stem cell that induces repair and regeneration after myocardial infarction technical field |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140001900A (en) | 2014-01-07 |
| EP2630234A4 (en) | 2014-03-26 |
| SG189414A1 (en) | 2013-05-31 |
| CN104204190A (en) | 2014-12-10 |
| TW201231663A (en) | 2012-08-01 |
| US9234177B2 (en) | 2016-01-12 |
| US20120094380A1 (en) | 2012-04-19 |
| AU2011317203A2 (en) | 2013-06-27 |
| CA2815097A1 (en) | 2012-04-26 |
| AU2011317203B2 (en) | 2016-10-20 |
| EP2630234A1 (en) | 2013-08-28 |
| WO2012054501A9 (en) | 2013-05-30 |
| US20160145577A1 (en) | 2016-05-26 |
| CN104204190B (en) | 2017-02-01 |
| AU2011317203A1 (en) | 2013-06-06 |
| EP2630234B1 (en) | 2017-12-13 |
| TWI523947B (en) | 2016-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9234177B2 (en) | Human multipotent embryonic stem cell-like progenitor cells | |
| Lodie et al. | Systematic analysis of reportedly distinct populations of multipotent bone marrow-derived stem cells reveals a lack of distinction | |
| EP2609191B1 (en) | Non-static suspension culture of cell aggregates | |
| Salehinejad et al. | Comparison of different methods for the isolation of mesenchymal stem cells from human umbilical cord Wharton’s jelly | |
| US20100105132A1 (en) | Human Mesenchymal stem cells and preparation thereof | |
| EP2374871B1 (en) | Pluripotent stem cells, method for preparation thereof and uses thereof | |
| Montesinos et al. | Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression | |
| RU2252252C1 (en) | Method for isolation of mesenchymal stem cells | |
| EP3342857A1 (en) | Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue | |
| Yen et al. | Placenta-derived multipotent cells differentiate into neuronal and glial cells in vitro | |
| US7781211B2 (en) | Isolation of multi-lineage stem cells | |
| KR101193541B1 (en) | Method of inducing differentiation of human embryonic stem cells into mesenchymal stem cells | |
| Barachini et al. | Morpho-functional characterization of human mesenchymal stem cells from umbilical cord blood for potential uses in regenerative medicine | |
| US20100166716A1 (en) | Colony-forming unit cell of human chorion and method to obtain and use thereof | |
| US20120251504A1 (en) | Pluripotent stem cells obtained from dental pulp | |
| Thilakavathy et al. | Characteristics of full-term amniotic fluid-derived mesenchymal stem cells in different culture media | |
| US20080081370A1 (en) | Directed differentiation of human embryonic stem cells into mesenchymal/stromal cells | |
| Miao et al. | Isolation and characterization of human chorionic membranes mesenchymal stem cells and their neural differentiation | |
| Tsai et al. | Expression of a Hoechst 33342 efflux phenomenon and common characteristics of pluripotent stem cells in a side population of amniotic fluid cells | |
| Zhang et al. | Isolation, Culture, Identification and Differentiation of Canine Amniotic Mesenchymal Stem Cells in Vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11835003 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2815097 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011835003 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 20137012722 Country of ref document: KR Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2011317203 Country of ref document: AU Date of ref document: 20111018 Kind code of ref document: A |